News | September 16, 2014

New Analysis Addresses Cardiovascular Patients With Other Conditions

First attempt to tackle clinical decisions compounded by other treated comorbidities


September 16, 2014 — A quarter of adults in the United States have two or more chronic medical conditions, as do more than two-thirds of seniors, yet there are few clinical practice guidelines for cardiologists that take such comorbid conditions and their treatment into consideration.

An article jointly developed by the American College of Cardiology (ACC), the American Heart Association (AHA) and the U.S. Department of Health and Human Services (HHS) hopes to raise awareness and provide advice for cardiologists treating cardiovascular disease patients who are taking drugs for a range of other common health problems, especially the elderly.

The authors reviewed Medicare claims for 2012 to determine the extent to which cardiovascular patients were filing claims for a range of other conditions such as pulmonary dysfunction, diabetes mellitus, arthritis and mental health disorders. The analysis focused on four major cardiovascular conditions: ischemic heart disease, heart failure, atrial fibrillation and stroke. In all, 8,678,060 patients had claims for ischemic heart disease; 4,366,489 with heart failure; 2,556,839 with atrial fibrillation; and 1,145,719 with stroke.

As was expected, hypertension and high cholesterol were the most common comorbidities for most of the major cardiovascular conditions. Notably, diabetes and arthritis were also very common in individuals with these conditions. For example, diabetes was a comorbidity in 41.7 percent of those with ischemic heart disease, 47.1 percent among heart failure patients, 37.1 percent in atrial fibrillation patients and 41.5 percent in stroke patients. Arthritis was a comorbidity in 40.6 percent of those with ischemic heart disease, 45.6 percent among heart failure patients, 41.7 percent in atrial fibrillation patients and 44.2 percent in stroke patients. The analysis also revealed the presence of comorbidities such as chronic kidney disease, chronic obstructive pulmonary disease, Alzheimer’s disease/dementia and depression among individuals with these cardiovascular conditions. For example, 26.3 percent of heart failure patients had Alzheimer’s disease/dementia, and 29.7 percent of stroke patients had depression.

“Although data in the medical literature is somewhat limited, some medications given to patients with these other conditions can interfere with those used for cardiovascular disease and, in some cases, even pose serious health risks,” said William A. Zoghbi, M.D., director of cardiovascular imaging at the Houston Methodist DeBakey Heart and Vascular Center, past president of the ACC and an author of the article.

Donna K. Arnett, M.S.P.H., Ph.D., professor and chair of the department of epidemiology in the School of Public Health at University of Alabama Birmingham and past president of the AHA, who helped develop the article, said that the increase in so many comorbidities in aging patients with cardiovascular disease is an important clinical problem and makes developing new guidelines critical.

“Incorporating major comorbidities into future clinical practice guidelines will be challenging, however this large analysis helps by identifying those comorbidities which are most prevalent,” she said, noting that ischemic heart disease is most common in the elderly, with nearly 9 million individuals over the age of 65 estimated to have the disease, while 81 percent have comorbid hypertension and 69 percent have hyperlipidemia.

Some existing cardiovascular guidelines include consideration of special treatment and potential complications due to these factors, such as patient age and problems affecting pharmacokinetics, notably kidney and liver function. But as a whole, with the exception of atrial fibrillation and heart failure, formal clinical practice guidelines have never before systematically identified and made recommendations on how common comorbidities in cardiovascular disease might affect care and management of patients.

For more information: www.cardiosource.org, www.americanheart.org


Related Content

News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
Subscribe Now